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Details of Amendments (V5 to V6)


The LFP View has been added to incorporate data from the new long-term follow-up form.

The SGN view has been updated with the long-term follow-up form.

The COM view has been updated with the long-term follow-up form.







This version (V5) of Appendix II incorporates all changes made on CRFs up until 24 May 2013.  For reference, current versions of CRFs are:

	Site Questionnaire v5 030311
	Randomisation Form v4 060712
	Wk 12 Randomisation Form v2 130608
	Treatment Form v4 240513
	Follow-up Form v4 190116
	EORTC QLQ-C30 v2 060309
	EQ-5D Questionnaire v3 190116
	GOG NTX 4 v4 190116
	Consent Withdrawal Notification Form v2 010408
	Patient Withdrawal Questionnaire v1 170709
	High Risk Stage II Patients – Additional Information v1 29 Jan 2013
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The table in this section details the Oracle views that are used to produce data listings for this study. The table is headed with the view name. For each view the field name (in Oracle), form type, field name (on the CRF, including the section) and coding or field type are listed. Fields highlighted in pink are not  accessible to statisticians via the views.


The coding or field type is generally in one of the following format:

	The study number (GI145);
	A number value – the number value format will be recorded as follows,
Example: (Number f99.9), where f= fixed format, 99 is the number of digits expected before the decimal point (in this case 2), a decimal point, and 9 is the number of digits expected after the decimal point (in this case 1);
	Free text;
	A date;
	The answer options in relation to the question for e.g. 1;2;3;
	The answer option in relation to a question which can have a tick for the answer will be coded as 1=Ticked; Null=Not ticked.

Oracle view name: GI145_SITRAN_V6(SITRAN) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
PI	Site Randomisation Method Questionnaire	Principal Investigator	From authorised list
HOSP	Site Randomisation Method Questionnaire	Hospital Name	From authorised list
RESPCTU	Site Randomisation Method Questionnaire	Responsible CTU	1=CRUK CTU Glasgow; 2=OCTO
QOL (Not on V5 of form)	Site Randomisation Method Questionnaire	Participating in QOL?	1=Yes; 2=No
SCOTNUM	Site Randomisation Method Questionnaire	Please estimate the combined total overall recruitment to the study for all hospitals listed above each year:	1=<5; 2=6-10; 3=11-15; 4=16-20; 5=21-25; 6=>25
RANDTIME	Site Randomisation Method Questionnaire	Randomisation time point allocated	U=Upfront Randomisation; D=Randomisation after 12 weeks
QUAS2	Site Randomisation Method Questionnaire	Is your site participating in the Quasar 2 study?	1=Yes; 2=No
QUAS2NUM	Site Randomisation Method Questionnaire	Quasar 2 Recruitment	1=<5; 2=6-10; 3=11-15; 4=16-20; 5=21-25; 6=>25
QOLP	Site Randomisation Method Questionnaire	QOL Participation	1=Yes; 2=No





Oracle view name: GI145_REG_V6(REG) XE "G84_REGISTRATION (REG)" 
Current registration data – can be updated




CALLT	Registration	Caller’s Telephone Number	Free Text
CALLF	Registration	Caller’s Fax Number	Free Text
HOSP	Registration	Site	From authorised list
DR	Registration	Investigator	From authorised list
INITIALF	Registration	Patient Initials (f)	Free Text
INITIALS	Registration	Patient Initials (s)	Free Text
GEND	Registration	Gender of Patient	M=Male; F=Female
DOB	Registration	Date of Birth	Date
Age	N/A	Does not appear on form: calculated on the database from DOB and REGDATE	Number (f99.99>0)
INC1-INC15	Registration	Inclusion questions 1-15	1=Yes; 2=No
EXC1-EXC6	Registration	Exclusion questions 16 - 21	1=Yes; 2=No
CTDATE	Registration	Date of CT Scan From Q2	Date
SURGDATE	Registration	Date of Surgery From Q3	Date
CYC1DT (only on v4 of from)	Registration	Date of cycle 1 From Q3	Date
PS	Registration	Performance Status from Q4	0; 1
CONSDATE	Registration	Date of Consent from Q7	Date
HAEDATE	Registration	Date of haematology	Date
BIODATE	Registration	Date of biochemistry	Date
RCEA	Registration	CEA from Q8	Number (f999.99)>=0
RCEADATE	Registration	Date of CEA	Date
RNEUT	Registration	Neutrophils from Q9	Number (f99.99)>=0
RPLAT	Registration	Platelets from Q10	Number (f999.99)>=0
RHB	Registration	Haemoglobin from Q11	Number (f99.99)>=0
RAST	Registration	AST from Q12	Number (f999.99)>=0
RALT	Registration	ALT from Q12	Number (f999.99)>=0
RCREAT	Registration	Calculated Creatinine Clearance from Q13	Number (f999.99)>=0
ECGDATE	Registration	Date of ECG	Date
WAIVER	Registration	If a waiver has been requested from the Chief Investigator to include a patient who is otherwise strictly ineligible please tick (field only on database)	1=ticked; Null=Not ticked
WAIVERDE	Registration	Details of waiver (field only on database)	Free Text
TRT	Registration	Planned Treatment	1=OxMdG; 2=Xelox
DISSITE	Registration	Disease Site	1=colon; 2=rectum
STAGET	Registration	T Stage	X; 0; 1; 2 :3:4
STAGEN	Registration	N Stage	0; 1; 2
STARTDOSE (only from version 3 on)	Registration	Starting dose of Xelox	1=750; 2=800; 3=1000




CHINO	Registration	NHS No./CHI No:	Free Text
PCODE	Registration	Post Code	Free Text
ETHNIC	Registration	Ethnic Group	1=White/Caucasian; 2=Black (African/Caribbean); 3=South Asian (Indian/Pakistani/Bangladeshi); 4=Chinese; 5=Mixed (specify); 6=Other (specify); 7=Patient Refusal
MXDSPEC	Registration	Further specification if ETHNIC=5 (Mixed)	Free Text
OTHRSPEC	Registration	Further specification if ETHNIC=6(Other)	Free Text
CONSENTQUEST (only on v2 and v3)	Registration	Consent for Blood and Tissue	1=Yes; 2=No
TISSUE_CONSENT (only on v4)	Registration	Consent for Tissue	1=Yes; 2=No
BLOOD_CONSENT (only on v4)	Registration	Consent for Blood	1=Yes; 2=No
RQOL (not on v4)	Registration	Has the patient completed the EORTC QLQ-C30 and CR29 questionnaire?	1=Yes; 2=No
RQOLSPEC (not on v4)	Registration	Further specification if RQOL=2 (No)	Free Text
REQ5D (not on v4)	Registration	Has the patient completed the EQ-5D questionnaire?	1=Yes; 2=No
REQ5DSPEC (not on v4)	Registration	Further specification if REQ-5D=2 (No)	Free Text
RNEURO (not on v4)	Registration	Has the patient completed the GOG-NTX 4 questionnaire?	1=Yes; 2=No
NEUROSPEC	Registration	Further specification if RNEURO=2 (No)	Free Text
TRIALNO	Registration	Trial No	Number (f9999) > 0
REGDATE	Registration	Date of randomisation	Date
ARM	Registration	Treatment Assigned	12 weeks;24 weeks; 12 weeks of treatment and then randomise
DATECOMP	Registration	Date Form Completed	Date

Oracle view name: GI145_MASTER_REG_V6(MASTER_REG) XE "G84_REGISTRATION (REG)" 
Registration data at randomisation – cannot be updated (from patient 1959 on)




CALLT	Registration	Caller’s Telephone Number	Free Text
CALLF	Registration	Caller’s Fax Number	Free Text
HOSP	Registration	Site	From authorised list
DR	Registration	Investigator	From authorised list
INITIALF	Registration	Patient Initials (f)	Free Text
INITIALS	Registration	Patient Initials (s)	Free Text
GEND	Registration	Gender of Patient	M=Male; F=Female
DOB	Registration	Date of Birth	Date
Age	N/A	Does not appear on form: calculated on the database from DOB and REGDATE	Number (f99.99>0)
INC1-INC15	Registration	Inclusion questions 1-15	1=Yes; 2=No
EXC1-EXC6	Registration	Exclusion questions 16 - 21	1=Yes; 2=No
CTDATE	Registration	Date of CT Scan From Q2	Date
SURGDATE	Registration	Date of Surgery From Q3	Date
CYC1DT (only on v4 of from)	Registration	Date of cycle 1 From Q3	Date
PS	Registration	Performance Status from Q4	0; 1
CONSDATE	Registration	Date of Consent from Q7	Date
HAEDATE	Registration	Date of haematology	Date
BIODATE	Registration	Date of biochemistry	Date
RCEA	Registration	CEA from Q8	Number (f999.99)>=0
RCEADATE	Registration	Date of CEA	Date
RNEUT	Registration	Neutrophils from Q9	Number (f99.99)>=0
RPLAT	Registration	Platelets from Q10	Number (f999.99)>=0
RHB	Registration	Haemoglobin from Q11	Number (f99.99)>=0
RAST	Registration	AST from Q12	Number (f999.99)>=0
RALT	Registration	ALT from Q12	Number (f999.99)>=0
RCREAT	Registration	Calculated Creatinine Clearance from Q13	Number (f999.99)>=0
ECGDATE	Registration	Date of ECG	Date
WAIVER	Registration	If a waiver has been requested from the Chief Investigator to include a patient who is otherwise strictly ineligible please tick (field only on database)	1=ticked; Null=Not ticked
WAIVERDE	Registration	Details of waiver (field only on database)	Free Text
TRT	Registration	Planned Treatment	1=OxMdG; 2=Xelox
DISSITE	Registration	Disease Site	1=colon; 2=rectum
STAGET	Registration	T Stage	X; 0; 1; 2 :3:4
STAGEN	Registration	N Stage	0; 1; 2
STARTDOSE (only from version 3 on)	Registration	Starting dose of Xelox	1=750; 2=800; 3=1000




CHINO	Registration	NHS No./CHI No:	Free Text
PCODE	Registration	Post Code	Free Text
ETHNIC	Registration	Ethnic Group	1=White/Caucasian; 2=Black (African/Caribbean); 3=South Asian (Indian/Pakistani/Bangladeshi); 4=Chinese; 5=Mixed (specify); 6=Other (specify); 7=Patient Refusal
MXDSPEC	Registration	Further specification if ETHNIC=5 (Mixed)	Free Text
OTHRSPEC	Registration	Further specification if ETHNIC=6(Other)	Free Text
CONSENTQUEST (only on v2 and v3)	Registration	Consent for Blood and Tissue	1=Yes; 2=No
TISSUE_CONSENT (only on v4)	Registration	Consent for Tissue	1=Yes; 2=No
BLOOD_CONSENT (only on v4)	Registration	Consent for Blood	1=Yes; 2=No
RQOL (not on v4)	Registration	Has the patient completed the EORTC QLQ-C30 and CR29 questionnaire?	1=Yes; 2=No
RQOLSPEC (not on v4)	Registration	Further specification if RQOL=2 (No)	Free Text
REQ5D (not on v4)	Registration	Has the patient completed the EQ-5D questionnaire?	1=Yes; 2=No
REQ5DSPEC (not on v4)	Registration	Further specification if REQ-5D=2 (No)	Free Text
RNEURO (not on v4)	Registration	Has the patient completed the GOG-NTX 4 questionnaire?	1=Yes; 2=No
NEUROSPEC	Registration	Further specification if RNEURO=2 (No)	Free Text
TRIALNO	Registration	Trial No	Number (f9999) > 0
REGDATE	Registration	Date of randomisation	Date




Oracle view name: GI145_W12REG_V6(W12REG) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
FORMTYPE	-	-	GI145R12
CALL	Week 12 Registration	Caller’s Name	Free Text
CALLT	Week 12 Registration	Caller’s Telephone Number	Free Text
CALLF	Week 12 Registration	Caller’s Fax Number	Free Text
TRIALNO	Week 12 Registration	Allocated patient trial number	Number (f9999) > 0
DOB	Week 12 Registration	Date of Birth	Date
GEND	Week 12 Registration	Gender of Patient	M=Male; F=Female
INITIALF	Week 12 Registration	Patient Initials (f)	Free Text
INITIALS	Week 12 Registration	Patient Initials (s)	Free Text
DR	Week 12 Registration	Investigator	From authorised list
HOSP	Week 12 Registration	Site	From authorised list
STOPREASON	Week 12 Registration	Reason for patient not being randomised section	1 = Patient stopped treatment before 12 weeks (ensure details recorded on Treatment Form);2 = Patient not fit to receive more than 12 weeks of treatment  (ensure details recorded on Treatment Form);3 = Patient has withdrawn consent (Please complete Consent Withdrawal Form);4 = Other reason.
STOPOTHSPEC	Week 12 Registration	Reason for patient not being randomised section	Free Text
RQ1-RQ15	Week 12 Registration	Questions 1-15 on Week 12 Registration	1=Yes; 2=No
DATECONFIRMED	Week 12 Registration	Date form completed for patients who are not randomised	Date
RPS	Week 12 Registration	Performance Status from Q2	0; 1
HAEDATE	Week 12 Registration	Date of haematology	Date
BIODATE	Week 12 Registration	Date of biochemistry	Date
RCEA	Week 12 Registration	CEA from Q4	Number (f999.99)>=0
RCEADATE	Week 12 Registration	Date of CEA	Date
RNEUT	Week 12 Registration	Neutrophils from Q5	Number (f99.99)>=0
RPLAT	Week 12 Registration	Platelets from Q6	Number (f999.99)>=0
RHB	Week 12 Registration	Haemoglobin from Q7	Number (f99.99)>=0
RAST	Week 12 Registration	AST from Q8	Number (f999.99)>=0
RALT	Week 12 Registration	ALT from Q8	Number (f999.99)>=0
RCREAT	Week 12 Registration	Calculated Creatinine Clearance from Q9	Number (f999.99)>=0
WAIVER	Week 12 Registration	If a waiver has been requested from the Chief Investigator to include a patient who is otherwise strictly ineligible please tick (field only on database)	1=ticked; Null=Not ticked
WAIVERDE	Week 12 Registration	Details of waiver (field only on database)	Free Text
TRT	Week 12 Registration	Planned Treatment	1=OxMdG; 2=Xelox
ARM	Week 12 Registration	Treatment Assigned	12 weeks (stop treatment); 24 weeks (Continue for a further 12 weeks of treatment)
REGDATE	Week 12 Registration	Date of Randomisation	Date
DATECOMP	Week 12 Registration	Date Form Completed for patients who are randomised	Date

Oracle view name: GI145_CNWI_5 (CNWI) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145CWF
FORMSEQ	-	-	Number (f99) >0
DATEW1	Consent Withdrawal Notification	Date Patient Withdrew Consent	Date
PERSONNAME	Consent Withdrawal Notification	Name of person (clinician or appropriate designee) who discussed consent withdrawal with the patient	Free Text
DISC	Consent Withdrawal Notification	Was the person who discussed withdrawal with the patient present when the patient signed the Consent Withdrawal Form?	1=Yes; 2=No
FLUP	Consent Withdrawal Notification	Has the patient withdrawn consent from further trial-related follow up?	1=Yes; 2=No
BLOOD	Consent Withdrawal Notification	Has the patient withdrawn consent of further research on blood samples collected?	1=Yes; 2=No; 3=N/A
TISS	Consent Withdrawal Notification	Has the patient withdrawn consent of further research on tissue samples collected?	1=Yes; 2=No; 3=N/A
URINE	Consent Withdrawal Notification	Has the patient withdrawn consent of further research on urine samples collected?	1=Yes; 2=No; 3=N/A
PRIORTODATA	Consent Withdrawal Notification	Has the patient withdrawn consent to the use of data collected prior to the date Consent Withdrawal Form was signed?	1=Yes; 2=No
SIGPAT	Consent Withdrawal Notification	Has the Consent Withdrawal Form been correctly signed and dated by the patient?	1=Yes; 2=No
SIGCLI	Consent Withdrawal Notification	Has the Consent Withdrawal Form been correctly signed and dated by the clinician/appropriate designee?	1=Yes; 2=No
VERS	Consent Withdrawal Notification	Version of Consent Withdrawal Form used	Number (f9.9)
CWDATE	Consent Withdrawal Notification	Date of Consent Withdrawal Form used	Date
COPY	Consent Withdrawal Notification	Has the patient been provided with a copy of the completed Consent Withdrawal Form?	1=Yes; 2=No
FILED	Consent Withdrawal Notification	Has the original Consent Withdrawal Form been filed appropriately on site?	1=Yes; 2=No
NOREAS	Consent Withdrawal Notification	If FILED=2 (No), further specification required	Free Text


Oracle view name: GI145_QOL_V6(QOL) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMSEQ	-	-	Number (f99) >0
FORMTYPE	-	-	GI145QLQ
TIMEPOINT	QOL	Questionnaire Completed at:	1=Baseline (up to 7 days prior to registration/randomisation); 2=Treatment (Cycles 1-3 of OxMdG, Cycles 1-2 of Xelox); 3=Treatment (Cycles 4-6 of OxMdG, Cycles 3-4 of Xelox); 4=Treatment (Cycles 7-9 of OxMdG, Cycles 5-6 of Xelox); 5=Treatment (Cycles 10-12 of OxMdG, Cycles 7-8 of Xelox); 6=Follow up (Month 4); 7=Follow up (Month 5); 8=Follow up (Month 6); 9=Follow up (Month 9);10=Follow up (Month 12)
QOLDATE	QOL	Today’s Date	Date
QOL1-28; QOL31-47	QOL	QOL Questions 1-28 and 31-47	1; 2; 3; 4
QOL29-30	QOL	QOL Questions 29 and 30	1; 2; 3; 4; 5; 6; 7
QOL48	QoL	QOL Question 48	1=Yes; 2=No
QOL49S-55S	QOL	QOL Questions 49-55 (ONLY IF YOU HAVE A STOMA BAG) 	1; 2; 3; 4
QOL49-54	QOL	QOL Questions 49-54  (ONLY IF YOU DO NOT HAVE A STOMA BAG)	1; 2; 3; 4
QOL56-59	QOL	QOL Questions 56-59	1; 2; 3; 4

Oracle view name: GI145_EQ5D_V6(EQ5D) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145EQ5
FORMSEQ	-	-	Number (f99) >=0
TIMEPOINT	EQ5D	Questionnaire Completed at:	1=Baseline (up to 7 days prior to registration/randomisation); 2=Treatment (Cycles 1-3 of OxMdG, Cycles 1-2 of Xelox); 3=Treatment (Cycles 4-6 of OxMdG, Cycles 3-4 of Xelox); 4=Treatment (Cycles 7-9 of OxMdG, Cycles 5-6 of Xelox); 5= Treatment (Cycles 10-12 of OxMdG, Cycles 7-8 of Xelox); 6=Follow up (Month 4); 7=Follow up (Month 5); 8=Follow up (Month 6); 9=Follow up (Month 9); 10=Follow up (Month 12); 11=Follow up (Month 18); 12= Follow up (Year 2); 13=Follow up (Year 3) ; 14=Follow up (Year 4) ; 15= Follow up (Year 5); 16=Follow up (Year 6): 17=Follow up (Year 7);18=Follow up (Year 8);19=Follow up (Year 9)
EQ5DDATE	EQ5D	Date Completed	Date
MOB	EQ5D	Mobility	1=I have no problems walking about; 2=I have some problems in walking about; 3= I am confined to bed 
SELF	EQ5D	Self Care 	1=I have no problems with self-care; 2= I have some problems washing or dressing myself; 3= I am unable to wash or dress myself
USUAL	EQ5D	Usual Activities	1= I have no problems with performing my usual activities; 2= I have some problems with performing my usual activities; 3= I am unable to perform my usual activities
PAIN	EQ5D	Pain/Discomfort 	1= I have no pain or discomfort; 2= I have moderate pain or discomfort; 3= I have extreme pain or discomfort
ANX	EQ5D	Anxiety/Depression 	1= I am not anxious or depressed; 2= I am moderately anxious or depressed; 3=I am extremely anxious or depressed
HEALTH	EQ5D	Your own health state today	Number 1-100

Oracle view name: GI145_NEUR_V6(NEUR) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145NTX
FORMSEQ	-	-	Number (f99) >0
TIMEPOINT	GOG NTX 4	Questionnaire Completed at:	1=Baseline (up to 7 days prior to registration/randomisation); 2=Treatment (Cycles 1-3 of OxMdG, Cycles 1-2 of Xelox); 3=Treatment (Cycles 4-6 of OxMdG, Cycles 3-4 of Xelox); 4=Treatment (Cycles 7-9 of OxMdG, Cycles 5-6 of Xelox); 5=Treatment (Cycles 10-12 of OxMdG, Cycles 7-8 of Xelox); 6=Follow up (Month 4); 7=Follow up (Month 5); 8=Follow up (Month 6); 9=Follow up (Month 9);10=Follow up (Month 12); 11=Follow up (Month 18); 12=Follow Up (Year 2) ; 13=Follow Up (Year 3) ; 14=Follow Up (Year 4) ; 15=Follow Up (Year 5) ; 16=Follow Up (Year 6) ; 17=Follow Up (Year 7);18=Follow up (Year 8);19=Follow up (Year 9)
NEURDATE	GOG NTX 4	Date Completed	Date
Q1-4	GOG NTX 4	Neurotoxicity questions 1-4	0; 1; 2; 3; 4

Oracle view name: GI145_CHEMO_V6(CHM) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145TRT
FORMSEQ	-	-	Number (f99) >=0
TIMEPOINT	Treatment	Tick to indicate the treatment period covered by this form (tick one only)	1= First 6 weeks of treatment approximately (cycles 1-3 of OxMdG; cycles 1-2 of Xelox); 2= Weeks 7-12 of treatment approximately (cycles 4-6 of OxMdG; cycles 3-4 of Xelox); 3= Weeks 13-18 of treatment approximately (cycles 7-9 of OxMdG; cycles 5-6 of Xelox); 4= Weeks 19-24 of treatment approximately (cycles 10-12 of OxMdG; cycles 7-8 of Xelox)
HEIGHT	Treatment	Patient’s Height (m) 	Number (f9.99) > 0
CYCNO1	Treatment	Cycle No. – Treatment Delivery	Number (f99) > 0
CYCNO2	Treatment	Cycle No. – Treatment Delivery	Number (f99) > 0
CYCNO3	Treatment	Cycle No. – Treatment Delivery	Number (f99) > 0
CYCDT1	Treatment	Cycle date - Treatment Delivery	Date
CYCDT2	Treatment	Cycle date - Treatment Delivery	Date
CYCDT3	Treatment	Cycle date - Treatment Delivery	Date
TRT1	Treatment	Type of treatment - Treatment Delivery	1=Xelox; 2=OxMdG
TRT2	Treatment	Type of treatment - Treatment Delivery	1=Xelox; 2=OxMdG
TRT3	Treatment	Type of treatment - Treatment Delivery	1=Xelox; 2=OxMdG
WEIGHT1	Treatment	Weight (kg) - Treatment Delivery	Number (f999.9) > 0
WEIGHT2	Treatment	Weight (kg) - Treatment Delivery	Number (f999.9) > 0
WEIGHT3	Treatment	Weight (kg) - Treatment Delivery	Number (f999.9) > 0
CHEMDEL1	Treatment	Was cycle delayed? - Treatment Delivery	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CHEMDEL2	Treatment	Was cycle delayed? - Treatment Delivery	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CHEMDEL3	Treatment	Was cycle delayed? - Treatment Delivery	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CHEMDELSPEC1	Treatment	Further specification if CHEMDEL1=9 (Other or combination)	Free Text
CHEMDELSPEC2	Treatment	Further specification if CHEMDEL2=9 (Other or combination)	Free Text
CHEMDELSPEC3	Treatment	Further specification if CHEMDEL3=9 (Other or combination)	Free Text
T5FUB1	Treatment	Total 5-FU dose (mg) bolus – Treatment Delivery	Number (f9999) > 0
T5FUB2	Treatment	Total 5-FU dose (mg) bolus – Treatment Delivery	Number (f9999) > 0
T5FUB3	Treatment	Total 5-FU dose (mg) bolus – Treatment Delivery	Number (f9999) > 0
T5FUIV1	Treatment	Total 5-FU dose (mg) iv – Treatment Delivery	Number (f99999) > 0
T5FUIV2	Treatment	Total 5-FU dose (mg) iv – Treatment Delivery	Number (f99999) > 0
T5FUIV3	Treatment	Total 5-FU dose (mg) iv – Treatment Delivery	Number (f99999) > 0
CAPPRES1	Treatment	Dose of capecitabine prescribed for this cycle (mg) – Treatment Delivery	Number (f9999) > 0
CAPPRES2	Treatment	Dose of capecitabine prescribed for this cycle (mg) – Treatment Delivery	Number (f9999) > 0
CAPPRES3	Treatment	Dose of capecitabine prescribed for this cycle (mg) – Treatment Delivery	Number (f9999) > 0
CAP5FURED1	Treatment	Was the total 5-FU dose or prescribed capecitabine dose less than the protocol amount (cycle 1) or dose reduced compared to previous cycles? – Treatment Delivery	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CAP5FURED2	Treatment	Was the total 5-FU dose or prescribed capecitabine dose less than the protocol amount (cycle 1) or dose reduced compared to previous cycles? – Treatment Delivery 	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CAP5FURED3	Treatment	Was the total 5-FU dose or prescribed capecitabine dose less than the protocol amount (cycle 1) or dose reduced compared to previous cycles? – Treatment Delivery 	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CAP5FUREDSPEC1	Treatment	Further specification if  CAP5FURED1=9 (Other or combination) – Treatment Delivery	Free Text
CAP5FUREDSPEC2	Treatment	Further specification if  CAP5FURED2=9 (Other or combination) – Treatment Delivery	Free Text
CAP5FUREDSPEC3	Treatment	Further specification if  CAP5FURED3=9 (Other or combination) – Treatment Delivery	Free Text
CAPLESS1	Treatment	Did the patient take less than their prescribed capecitabine dose? – Treatment Delivery	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CAPLESS2	Treatment	Did the patient take less than their prescribed capecitabine dose? – Treatment Delivery	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CAPLESS3	Treatment	Did the patient take less than their prescribed capecitabine dose? – Treatment Delivery	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CAPLESSSPEC1	Treatment	Further specification if  CAPLESS1=9 (Other or combination) – Treatment Delivery	Free Text
CAPLESSSPEC2	Treatment	Further specification if  CAPLESS2=9 (Other or combination) – Treatment Delivery	Free Text
CAPLESSSPEC3	Treatment	Further specification if  CAPLESS3=9 (Other or combination) – Treatment Delivery	Free Text
OX1	Treatment	Total oxaliplatin dose (mg)	Number (f999) > 0
OX2	Treatment	Total oxaliplatin dose (mg)	Number (f999) > 0
OX3	Treatment	Total oxaliplatin dose (mg)	Number (f999) > 0
OXRED1	Treatment	Was total oxaliplatin dose less than the protocol amount (cycle 1) or reduced compared to the previous cycles? – Treatment Delivery	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
OXRED2	Treatment	Was total oxaliplatin dose less than the protocol amount (cycle 1) or reduced compared to the previous cycles? – Treatment Delivery 	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
OXRED3	Treatment	 Was total oxaliplatin dose less than the protocol amount (cycle 1) or reduced compared to the previous cycles? – Treatment Delivery	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
OXREDSPEC1	Treatment	Further specification if  OXRED1=9 (Other or combination) – Treatment Delivery	Free Text
OXREDSPEC2	Treatment	Further specification if  OXRED2=9 (Other or combination)  – Treatment Delivery	Free Text
OXREDSPEC3	Treatment	Further specification if  OXRED3=9 (Other or combination)  – Treatment Delivery	Free Text
SAE1	Treatment	Please tick if the patient had any SAEs during the cycle? – Treatment Delivery	1=Yes; 2=No
SAE2	Treatment	Please tick if the patient had any SAEs during the cycle? – Treatment Delivery	1=Yes; 2=No
SAE3	Treatment	Please tick if the patient had any SAEs during the cycle? – Treatment Delivery	1=Yes; 2=No
CALMAG1	Treatment	Did the patient receive any calcium or magnesium supplements on this cycle? (Please tick one box per cycle as appropriate)	1=Yes; 2=No
CALMAG2	Treatment	Did the patient receive any calcium or magnesium supplements on this cycle? (Please tick one box per cycle as appropriate)	1=Yes; 2=No





Oracle view name: GI145_TRTCHNG_V6(TRTCHNG) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145TRT
FORMSEQ	-	-	Number (f99) >=0
TIMEPOINT	Treatment	Tick to indicate the treatment period covered by this form (tick one only)	1= First 6 weeks of treatment approximately (cycles 1-3 of OxMdG; cycles 1-2 of Xelox); 2= Weeks 7-12 of treatment approximately (cycles 4-6 of OxMdG; cycles 3-4 of Xelox); 3= Weeks 13-18 of treatment approximately (cycles 7-9 of OxMdG; cycles 5-6 of Xelox); 4= Weeks 19-24 of treatment approximately (cycles 10-12 of OxMdG; cycles 7-8 of Xelox)
OXSTOP	Treatment	Has the patient discontinued oxaliplatin due to toxicity over this period?	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
OXSTOPSPEC	Treatment	Further specification if  OXSTOP=9 (Other or combination)  – Treatment Delivery	Free Text
CROSSCAP	Treatment	Has the patient changed from capecitabine to 5-FU due to toxicity over this period?	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CROSSCAPSPEC	Treatment	Further specification if  CROSSCAP=9 (Other or combination)  – Treatment Delivery 	Free Text
CROSS5FU	Treatment	Has the patient changed from 5-FU to capecitabine due to toxicity over this period?	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box
CROSS5FUSPEC	Treatment	Further specification if  CROSS5FU=9 (Other or combination)  – Treatment Delivery	Free Text
CROSSCAP5FU	Treatment	Has the patient changed from capecitabine to 5-FU or 5-FU to capecitabine due to toxicity over this period?	1=No; 2=Neutropenia; 3=Thrombocytopenia; 4=Neutropenia & thrombocytopenia; 5=Neurotoxicity; 6=Diarrhoea; 7=Hand-foot Syndrome; 8=Non-compliance; 9=Other or combination, specify beside the box





Oracle view name: GI145_AE (AE) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145TRT
FORMSEQ	-	-	Number (f99) >=0
CYCNO	Treatment	Adverse Reactions	Number (f9) > 0
TIMEPOINT	Treatment	Tick to indicate the treatment period covered by this form (tick one only)	1= First 6 weeks of treatment approximately (cycles 1-3 of OxMdG; cycles 1-2 of Xelox); 2= Weeks 7-12 of treatment approximately (cycles 4-6 of OxMdG; cycles 3-4 of Xelox); 3= Weeks 13-18 of treatment approximately (cycles 7-9 of OxMdG; cycles 5-6 of Xelox); 4= Weeks 19-24 of treatment approximately (cycles 10-12 of OxMdG; cycles 7-8 of Xelox)
ROWNO	Treatment	Does not appear in form – indexes row in table	1;2;3;4;….29
AR	Treatment	Adverse Reactions – Adverse Reaction	Picked from a list of acceptable codes or hard coded toxicity from form
GRADE	Treatment	Adverse Reactions – Worst grade during cycle	0;1;2;3;4;5;6 (for ND)
SAEREF	Treatment	Adverse Reactions – SAE ref. no.	Number (f9999) >0
ARSPEC	Treatment	Other toxicity specification (not visible on paper CRF).	Free Text

Oracle view name: GI145_HEA_V6(HEA) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145TRT, GI145FUP
FORMSEQ	-	-	Number (f99) >=0
TIMEPOINT	TreatmentFollow up 	Treatment Form - Tick to indicate the treatment period covered by this form (tick one only)Follow up Form – Follow-up Visit	1= First 6 weeks of treatment approximately (cycles 1-3 of OxMdG; cycles 1-2 of Xelox); 2= Weeks 7-12 of treatment approximately (cycles 4-6 of OxMdG; cycles 3-4 of Xelox); 3= Weeks 13-18 of treatment approximately (cycles 7-9 of OxMdG; cycles 5-6 of Xelox); 4= Weeks 19-24 of treatment approximately (cycles 10-12 of OxMdG; cycles 7-8 of Xelox); 5=4 months; 6=5 months; 7=6 months; 8= 9 months; 9=12 months; 10=18 months; 11=2 years;  12=3 years; 13=4 years; 14=5 years; 15=6 years; 16=7 years; 17=Dead;18=Follow up (Year 8);19=Follow up (Year 9)(No 1-4 Treatment form No 5 onwards Follow up Form)
ICU	TreatmentFollow up	Over the period covered by this form how many nights has the patient spent in hospital in ICU – Health Economic Assessment	Number (f99) >=0
HDU	TreatmentFollow up	Over the period covered by this form how many nights has the patient spent in hospital in HDU – Health Economic Assessment	Number (f99) >=0
GEN	TreatmentFollow up 	Over the period covered by this form how many nights has the patient spent in hospital in General/Acute – Health Economic Assessment	Number (f99) >=0
IP	TreatmentFollow up 	Over the period covered by this form how many nights has the patient spent in hospital in In-patient Chemotherapy – Health Economic Assessment	Number (f99) >=0
OP	TreatmentFollow up 	Over the period covered by this form how many days has the patient attended hospital as an Outpatient – Health Economic Assessment	Number (f99) >=0
DC	TreatmentFollow up 	Over the period covered by this form how many days has the patient attended hospital as an Day Case – Health Economic Assessment	Number (f99) >=0

Oracle view name: GI145_CHQDT_V6(CHQDT) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145TRT
FORMSEQ	-	-	Number (f99) >=0
CYCNO1	Treatment 	Cycle No – Quality of Life and Neurotoxicity Assessment	Number (f99) >0
CYCNO2	Treatment 	Cycle No – Quality of Life and Neurotoxicity Assessment	Number (f99) >0
CYCNO3	Treatment 	Cycle No – Quality of Life and Neurotoxicity Assessment	Number (f99) >0
QOL1	Treatment 	Has the patient completed the EORTC C30 & CR29 Questionnaires – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box 
QOL2	Treatment 	Has the patient completed the EORTC C30 & CR29 Questionnaires – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box 
QOL3	Treatment 	Has the patient completed the EORTC C30 & CR29 Questionnaires – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box 
QOLSPEC1	Treatment 	Further specification if QOL1=5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text
QOLSPEC2	Treatment 	Further specification if QOL2=5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text
QOLSPEC3	Treatment 	Further specification if QOL3=5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text
EQ5D1	Treatment 	Has the patient completed EQ-5D – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box 
EQ5D2	Treatment 	Has the patient completed EQ-5D – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box 
EQ5D3	Treatment 	Has the patient completed EQ-5D – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box 
EQ5DSPEC1	Treatment 	Further specification if EQ-5D1= 5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text
EQ5DSPEC2	Treatment 	Further specification if EQ-5D2= 5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text
EQ5DSPEC3	Treatment 	Further specification if EQ-5D3= 5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text
GOGNTX41	Treatment 	Has the patient completed GOG-NTX4 – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box 
GOGNTX42	Treatment 	Has the patient completed GOG-NTX4 – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box 
GOGNTX43	Treatment 	Has the patient completed GOG-NTX4 – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box 
GOGNTX4SPEC1	Treatment 	Further specification if GOG-NTX41=5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text
GOGNTX4SPEC2	Treatment	Further specification if GOG-NTX42=5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text




Oracle view name: GI145_FUQDT_V6(FUQDT) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145FUP
FORMSEQ	-	-	Number (f99) >=0
QOL	Follow up	Has the patient completed the EORTC C30 & CR29 Questionnaires – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box; 6=EORTC and GOG questionnaires not required beyond 12 months
QOLSPEC	Follow up	Further specification if QOL=5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text
EQ5D	Follow up	Has the patient completed EQ-5D – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box
EQ5DSPEC	Follow up	Further specification if EQ-5D= 5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text
GOGNTX4	Follow up	Has the patient completed GOG-NTX4 – Quality of life and Neurotoxicity Assessment	1=Yes; 2=No patient refused; 3=No, patient relapsed; 4=No, patient unfit; 5=No, other – please specify beside box; 6=EORTC and GOG questionnaires not required beyond 12 months
GOGNTX4SPEC	Follow up	Further specification if GOG-NTX4=5 (No, other) – Quality of life and Neurotoxicity Assessment	Free Text


Oracle view name: GI145_FCH_V6(FCH) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145TRT
FORMSEQ	-	-	Number (f99) >=0
TIMEPOINT	Treatment	Tick to indicate the treatment period covered by this form (tick one only)	1= First 6 weeks of treatment approximately (cycles 1-3 of OxMdG; cycles 1-2 of Xelox); 2= Weeks 7-12 of treatment approximately (cycles 4-6 of OxMdG; cycles 3-4 of Xelox); 3= Weeks 13-18 of treatment approximately (cycles 7-9 of OxMdG; cycles 5-6 of Xelox); 4= Weeks 19-24 of treatment approximately (cycles 10-12 of OxMdG; cycles 7-8 of Xelox)
CONT	Treatment 	Future Study Treatment	1= The patient is continuing on study treatment; 2= The patient has permanently discontinued before completing allocated treatment duration; 3= The patient has completed allocated treatment duration; 4= The patient was allocated to be randomised after 12 weeks, but was not randomised at that time-point
DATEDIS	Treatment 	Date last had study treatment – Future Study Treatment	Date
DATECOMP	Treatment 	Date last had study treatment – Future Study Treatment	Date

Oracle view name: GI145_WITH_V6(WITH) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145TRT
FORMSEQ	-	-	Number (f99) >=0
TIMEPOINT	Treatment 	Tick to indicate the treatment period covered by this form (tick one only)	1= First 6 weeks of treatment approximately (cycles 1-3 of OxMdG; cycles 1-2 of Xelox); 2= Weeks 7-12 of treatment approximately (cycles 4-6 of OxMdG; cycles 3-4 of Xelox); 3= Weeks 13-18 of treatment approximately (cycles 7-9 of OxMdG; cycles 5-6 of Xelox); 4= Weeks 19-24 of treatment approximately (cycles 10-12 of OxMdG; cycles 7-8 of Xelox)
AE	Treatment 	Adverse Event – Reasons for Early Treatment Withdrawal	1=ticked; Null=Not ticked
VIO	Treatment 	Protocol violation/ineligibility - Reasons for Early Treatment Withdrawal	1=ticked; Null=Not ticked
VIOSPEC	Treatment 	Further specification if VIO=1 (ticked) – Reasons for Early Treatment Withdrawal	Free Text
CLIN	Treatment 	Clinical decision - Reasons for Early Treatment Withdrawal	1=ticked; Null=Not ticked
CLINSPEC	Treatment 	Further specification if CLIN=1 (ticked) – Reasons for Early Treatment Withdrawal	Free Text
PAT	Treatment 	Patient decision - Reasons for Early Treatment Withdrawal	1=ticked; Null=Not ticked
PATSPEC	Treatment 	Further specification if PAT=1 (ticked) – Reasons for Early Treatment Withdrawal	Free Text
REC	Treatment 	Recurrence - Reasons for Early Treatment Withdrawal	1=ticked; Null=Not ticked
DEA	Treatment 	Death - Reasons for Early Treatment Withdrawal	1=ticked; Null=Not ticked
OTH	Treatment 	Other - Reasons for Early Treatment Withdrawal	1=ticked; Null=Not ticked
OTHSPEC	Treatment 	Further specification if OTH=1 (ticked) – Reasons for Early Treatment Withdrawal	Free Text
NEUT	Treatment 	Neutropenia – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
STOM	Treatment 	Stomatitis – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
ANAE	Treatment 	Anaemia – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
NAUS	Treatment 	Nausea – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
THROM	Treatment 	Thrombocytopenia – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
MUCOS	Treatment 	Mucositis – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
DIARR	Treatment 	Diarrhoea – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
VOM	Treatment 	Vomiting – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
PERNEUR	Treatment 	Peripheral Neuropathy – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
AEOTH	Treatment 	Other – Adverse Events Associated with Early Treatment Withdrawal	1=ticked; Null=Not ticked
AEOTHSPEC	Treatment 	Further specification if OTH=1 (ticked) – Adverse Events Associated with Early Treatment Withdrawal	Free Text


Oracle view name: GI145_MIX_V6(MIX) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145TRT; GI145FUP
FORMSEQ	-	-	Number (f99) >=0
AE	Treatment	Tick if you have been told by the SCOT office that documenting these toxicities on the CRF is no longer required – Adverse Reactions	1=ticked; Null=Not ticked
QOLNEUR	TreatmentFollow up	Tick if you have been told by SCOT office these assessments are no longer required or your centre is not participating in this aspect – Quality of Life and Neurotoxicity Assessment	1=ticked; Null=Not ticked
HEA	Follow upTreatment	Tick if you have been told by SCOT office these assessments are no longer required – Heath Economic Assessment	1=ticked; Null=Not ticked
PREVREC	Follow up	If the patient has had a confirmed recurrence on a previous form please tick - Details of first recurrence	1=ticked; Null=Not ticked
NOTASS	Follow up	If the patient’s disease was not assessed at this visit please tick – Details of first recurrence	1=ticked; Null=Not ticked
INI	Follow up	Anti-cancer Treatment Since Last Study Form Completed	1= No, anti-cancer treatment initiated since last study form completed; 2= Anti-cancer treatment initiated since last study form completed


Oracle view name: GI145_SURV_V6(SURV) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDY NO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145FUP
FORMSEQ	-	-	Number (f99) >=0
TIMEPOINT	Follow up	Follow-up Visit	1=4 months; 2=5 months; 3=6 months; 4= 9 months; 5=12 months; 6=18 months; 7=2 years;  8=3 years; 9=4 years; 10=5 years; 11=6 years; 12=7 years; 13=Dead;14=8 years;15=9 years
ALIVE	Follow up	Survival Status	1=Alive; 2=Not seen since last follow-up form completed – will be followed up at a future date; 3=Lost to follow-up, no further follow-up will be available; 4=Patient has withdrawn from the study; 5=Dead
DATEALIVE	Follow up	Date last known alive – Survival Status	Date
DATELOST	Follow up	Date lost to follow-up – Survival Status	Date
DATEWITH	Follow up	Date of withdrawal – Survival Status	Date
DATEDEAD	Follow up	Date of death – Survival Status	Date
CAUSE	Follow up	Survival Status:  Cause of Death	1=Colorectal cancer; 2=Protocol treatment related; 3=Other cancer; 4=Other treatment related; 5=Other causes; 6=Unknown




Oracle view name: GI145_SLV_V6(SLV) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDY NO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145FUP
FORMSEQ	-	-	Number (f99) >=0
TIMEPOINT	Follow up	Follow-up Visit	1=4 months; 2=5 months; 3=6 months; 4= 9 months; 5=12 months; 6=18 months; 7=2 years;  8=3 years; 9=4 years; 10=5 years; 11=6 years; 12=7 years; 13=Dead; 14= 8 years; 15= 9 years
REAS	Follow up	Reason - Anti-Cancer Treatment Initiated Since Last Study Form Completed	1=Confirmed recurrence; 2=Other, specify
REASSPEC	Follow up	Further specification if REAS=2 (Other)	Free Text
TRT1	Follow up	Anti-cancer Treatments - Anti-Cancer Treatment Initiated Since Last Study Form Completed	1=Capecitabine; 2=Irinotecan; 3=Oxaliplatin; 4=5-FU; 5=Mitomycin; 6=Avastin; 7=Cetuximab; 8=Pamitumumab; 9=Radiotherapy; 10=Radical Surgery; 11=Palliative surgery; 12=Other, specify
TRT2	Follow up	Anti-cancer Treatments - Anti-Cancer Treatment Initiated Since Last Study Form Completed	1=Capecitabine; 2=Irinotecan; 3=Oxaliplatin; 4=5-FU; 5=Mitomycin; 6=Avastin; 7=Cetuximab; 8=Pamitumumab; 9=Radiotherapy; 10=Radical Surgery; 11=Palliative surgery; 12=Other, specify
TRT3	Follow up	Anti-cancer Treatments - Anti-Cancer Treatment Initiated Since Last Study Form Completed	1=Capecitabine; 2=Irinotecan; 3=Oxaliplatin; 4=5-FU; 5=Mitomycin; 6=Avastin; 7=Cetuximab; 8=Pamitumumab; 9=Radiotherapy; 10=Radical Surgery; 11=Palliative surgery; 12=Other, specify
TRT4	Follow up	Anti-cancer Treatments - Anti-Cancer Treatment Initiated Since Last Study Form Completed	1=Capecitabine; 2=Irinotecan; 3=Oxaliplatin; 4=5-FU; 5=Mitomycin; 6=Avastin; 7=Cetuximab; 8=Pamitumumab; 9=Radiotherapy; 10=Radical Surgery; 11=Palliative surgery; 12=Other, specify
TRT5	Follow up	Anti-cancer Treatments - Anti-Cancer Treatment Initiated Since Last Study Form Completed	1=Capecitabine; 2=Irinotecan; 3=Oxaliplatin; 4=5-FU; 5=Mitomycin; 6=Avastin; 7=Cetuximab; 8=Pamitumumab; 9=Radiotherapy; 10=Radical Surgery; 11=Palliative surgery; 12=Other, specify
TRTSPEC	Follow up	Further specification if TRT1-5=12 (Other)	Free Text
STARTDATE	Follow up	Date started - Anti-Cancer Treatment Initiated Since Last Study Form Completed	Date


Oracle view name: GI145_REC_V6(REC) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDY NO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145FUP
FORMSEQ	-	-	Number (f99) >=0
TIMEPOINT	Follow up	Follow-up Visit	1=4 months; 2=5 months; 3=6 months; 4= 9 months; 5=12 months; 6=18 months; 7=2 years;  8=3 years; 9=4 years; 10=5 years; 11=6 years; 12=7 years; 13=Dead; 14 = 8 years; 15 = 9 years
CT	Follow up	Has a CT scan been performed since the last follow-up visit? – CT Scan	1=Yes; 2= No, patient recurred or evidence of new tumour confirmed previously; 3= No, scan not due (months 4, 5 and 9); 4= No, other reason; 5 = No, ultrasound of liver or chest x-ray performed.
CTDATE	Follow up	Date scan performed – CT Scan	Date
ULVDATE	Follow up	Ultrasound of Liver performed on – Ultrasound of Liver	Date
CXRDATE	Follow up	Chest X-ray performed on – Chest X-ray	Date
CTOTHSPEC	Follow up	Further specification if CT=4 (No, other reason) –  CT Scan	Free Text
REC	Follow up	Details of First Recurrence	1=No Recurrence; 2= Suspected recurrence; 3= Confirmed recurrence; 5 = Confirmed recurrence or evidence of a new tumour on a previous form; 4 = Disease status was not assessed at this visit.
DATECON	Follow up	Date confirmed – Details of First Recurrence	Date
LOCNODES	Follow up	Confirmed recurrence site(s): Local Nodes – Details of First Recurrence	1=ticked; Null=Not ticked
REGNODES	Follow up	Confirmed recurrence site(s): Regional Nodes – Details of First Recurrence	1=ticked; Null=Not ticked
DISNODES	Follow up	Confirmed recurrence site(s): Distant Nodes – Details of First Recurrence	1=ticked; Null=Not ticked
LIVER	Follow up	Confirmed recurrence site(s): Liver – Details of First Recurrence	1=ticked; Null=Not ticked
LUNG	Follow up	Confirmed recurrence site(s): Lung – Details of First Recurrence	1=ticked; Null=Not ticked
BONE	Follow up	Confirmed recurrence site(s): Bone – Details of First Recurrence	1=ticked; Null=Not ticked
OTHER	Follow up	Confirmed recurrence site(s): Other – Details of First Recurrence	1=ticked; Null=Not ticked
OTHERSPEC	Follow up	Further specification if OTHER=1 (ticked) – Details of First Recurrence	Free text
NEWTUM	Follow up	Has the patient evidence of new tumour – Evidence of New Tumour	1=No; 2=Yes
NEWTUMSPEC	Follow up	Specify site(s) if NEWTUM=2 (Yes) – Evidence of New Tumour	Free text


Oracle view name: GI145_SGN_V6(SGN) XE "G84_REGISTRATION (REG)" 





SIGNED	TreatmentFollow upConsent Withdrawal NotificationHigh Risk Stage II	Signature present on form	1=ticked; Null=Not ticked
SIGDATE	TreatmentFollow upConsent Withdrawal Notification High Risk Stage IILong Term Follow-up	Date of completion	Date


Oracle view name: GI145_COM_V6(COM) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDYNO	-	-	GI145
TRIALNO	-	-	Number (f9999)>0
FORMTYPE	-	-	GI145TRT;GI145FUP;GI45CWF;GI145HRS;GI145NTX; GI145QLQ; GI145EQ5; GI145LFP
FORMSEQ	-	-	Number (f99) >=0
COMMENTS	All	Comment field only on database	Free Text


Oracle view name: GI145_PWQ_V6 (PWQ) XE "G84_REGISTRATION (REG)" 










Oracle view name: GI145_HR_V6 (HR) XE "G84_REGISTRATION (REG)" 





T4	High Risk Stage II	T4 Disease	1= Yes; 2 = No
T4_PERF	High Risk Stage II	Primary Tumour Perforation	1=ticked; Null=not ticked
T4_ADH	High Risk Stage II	Adherence	1=ticked; Null=not ticked
T4_PER_INV	High Risk Stage II	Peritoneal Involvement	1=ticked; Null=not ticked
OBS	High Risk Stage II	Primary Tumour Obstruction	1= Yes; 2 = No
IN_NOD_HAR	High Risk Stage II	Inadequate Nodal Harvest	1= Yes; 2 = No
NODES	High Risk Stage II	Number of nodes examined	Number
POOR_HIS	High Risk Stage II	Poorly Differentiated Histology	1= Yes; 2 = No
VASC_I	High Risk Stage II	Vascular Invasion	1= Yes; 2 = No
LYM_I	High Risk Stage II	Lymphatic Invasion	1= Yes; 2 = No
PERIN_I	High Risk Stage II	Perineural Invasion	1= Yes; 2 = No
OTH	High Risk Stage II	Other	1= Yes; 2 = No
OTH_SPEC	High Risk Stage II	Specification of other	Free text
XRT	High Risk Stage II	If the patient had a rectal tumour (as confirmed at trial entry), did they receive radiotherapy either pre-operatively or as part of their post-operative first-line treatment?	1= Yes; 2 = No; 3=N/A


Oracle view name: GI145_Long_Term_FUP_V6(LFP) XE "G84_REGISTRATION (REG)" 
Field name in Oracle view	Form types in which field appears	Field name on CRF – CRF section	Coding or field type
STUDY NO	-	-	GI145
TRIALNO	-	-	Number (f9999) > 0
FORMTYPE	-	-	GI145LTFUP
FORMSEQ	-	-	Number (f99) >=0
REC	Long-term Follow-up	Has this patient had a recurrence of their colorectal cancer	1=No; 2= Yes; 3=Unknown
DATEREC	Long-term Follow-up	If “Yes” date recurrence confirmed.	Date
NPRIM	Long-term Follow-up	Has this patient developed a new primary colorectal tumour	1=No; 2= Yes; 3=Unknown
DATENPRIM	Long-term Follow-up	If “Yes” date new primary colorectal tumour diagnosed	Date
STATUS	Long-term Follow-up	Most Recent Available Survival Status:	1=No further info; 2=Alive; 3=Dead
DATEALIVE	Long-term Follow-up	Date last known alive	Date
DATEDEAD	Long-term Follow-up	Date of death	Date
COLOCAUSE	Long-term Follow-up	Cause of death: Colorectal cancer	1=Yes; Null=No
OTHCANCAUSE	Long-term Follow-up	Cause of death: Other cancer	1=Yes; Null=No
OTHTRTCAUSE	Long-term Follow-up	Cause of death: Other treatment related	1=Yes; Null=No
OTHCAUSE	Long-term Follow-up	Cause of death: Other causes	1=Yes; Null=No
UKCAUSE	Long-term Follow-up	Cause of death: Unknown	1=Yes; Null=No
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